Quanterix Corp (QTRX) Stock Price & Analysis

Quanterix Corp (QTRX) fell 1.28% to USD 3.09 as of June 10, 2026 at 05:15 UTC, according to Nexqual real-time market data.

QTRX last closed at USD 3.13; the session ranged USD 2.9–3.26 on volume of 817,453 shares. Market capitalization is $145.56M, with a 52-week range of USD 2.4–8.77 (NGM). Source: Nexqual, June 10, 2026 at 05:15 UTC.

Key Statistics (as of June 10, 2026 at 05:15 UTC)

Technical Analysis (QTRX)

Nexqual's technical model rates QTRX "NEUTRAL" based on 2 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 05:15 UTC.

Analyst Ratings (QTRX)

Wall Street analysts rate QTRX "Hold" based on 3 analysts, with a mean price target of USD 4.33 (range USD 4–5), per Nexqual as of June 10, 2026 at 05:15 UTC.

Earnings (QTRX)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 05:15 UTC.

Financials & Fundamentals (QTRX)

Source: Nexqual, June 10, 2026 at 05:15 UTC.

Financial Health Score (QTRX)

Nexqual rates Quanterix Corp's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:15 UTC.

Ownership (QTRX)

Source: Nexqual, June 10, 2026 at 05:15 UTC.

Leadership (QTRX)

Quanterix Corp is led by Everett V. Cunningham (age 59), President, CEO & Director, per Nexqual as of June 10, 2026 at 05:15 UTC.

Major Backers & Investors (QTRX)

Notable institutional backers of Quanterix Corp include Ameriprise Financial, Inc., Portolan Capital Management, LLC, William Blair Investment Management, LLC, according to Nexqual as of June 10, 2026 at 05:15 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 05:15 UTC.

From Quanterix Corp's Latest SEC 10-K Filing (filed 2026-03-02)

Key Strengths & Strategy (as disclosed to the SEC)

• In addition, we provide contract research services and clinical laboratory testing services, including four Laboratory Developed Tests ("LDTs"), using our proprietary technology and platforms through our Accelerator Laboratory, which is certified under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA"), located in Bedford, Massachusetts (the "Accelerator Laboratory").
• Akoya commercializes proprietary instrument platforms, reagents, software, and services that offer end-to-end solutions to perform tissue analysis and spatial phenotyping from discovery through translational and clinical research and diagnostics.
• These assays are designed for use across our Spatial Biology platforms, including PhenoCycler, PhenoImager Fusion, and PhenoImager HT, depending on the assay format and level of multiplexing required.
• Simoa Multi-Marker Algorithmic Test Leveraging both the multiplexing and high sensitivity capability of Simoa, we have developed a multi-marker algorithmic test that combines five biomarkers (p-Tau 217, Aβ42, Aβ 40, NfL, and GFAP) and uses a proprietary algorithm for high accuracy plasma detection of amyloid pathology.

Partnerships

• Key Agreements Development Agreement and Supply Agreement with STRATEC In August 2011, as amended in November 2016 and July 2025, we entered into a Strategic Development Services and Equity Participation Agreement with STRATEC, pursuant to which STRATEC undertook the development of the Simoa HD instrument.
• Cooperation Agreement with Kent Lake Partners As previously disclosed, on August 4, 2025, we entered into a Cooperation Agreement (the "Cooperation Agreement") with Kent Lake PR LLC, the general partner of Kent Lake Partners LP (together, "Kent Lake"), pursuant to which we agreed to retain an executive search firm to identify a potential candidate to be appointed to our board of directors (the "Board").

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:15 UTC. This page is informational and not investment advice.